Clinical Trial of Alpelisib and Tucatinib in Patients with PIK3CA-Mutant HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
Shagisultanova, Elena
Wisinski, Kari B.
Gawryletz, Chelsea D.
Datko, Farrah M.
Medgyesy, Diana
Diamond, Jennifer R.
Borges, Virginia F.
Kabos, Peter
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-09-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-09-01
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Fisetin for the management of PIK3CA-mutant colorectal cancer
    Khan, Naghma
    Jajeh, Farah
    Miller, Devon
    Van Doorn, Rachel
    Eberhardt, Emily Lauren
    Halberg, Richard B.
    Mukhtar, Hasan
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Incorporating Neratinib Into Clinical Practice for Patients With HER2-Positive Metastatic Breast Cancer
    Isaacs, Claudine
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 12 - 15
  • [33] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients:: a clinical study
    Carabantes-Ocon, F.
    Saez-Lara, E.
    Burgos-Garcia, L.
    Villar-Chamorro, E.
    Casaus-Hazanas, A.
    Luna, S.
    Martinez, C.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [34] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
    F Carabantes-Ocón
    E Saez-Lara
    L Burgos-Garcia
    E Villar-Chamorro
    A Casaus-Hazañas
    S Luna
    C Martínez
    Breast Cancer Research, 9
  • [35] Interim safety and efficacy analysis of phase IB/II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer
    Shagisultanova, Elena
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    Brenner, Andrew J.
    Stopeck, Alison
    Mayordomo, Jose
    Diamond, Jennifer R.
    Kabos, Peter
    Borges, Virginia F.
    CANCER RESEARCH, 2021, 81 (04)
  • [36] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Prognostic role of PIK3CA mutational status in cell free DNA (cfDNA) from HER2-positive metastatic breast cancer patients
    Lee, K-H
    Lim, J.
    Min, A.
    Kim, S-G
    Kim, J-E
    Kim, T-Y
    Han, S-W
    Oh, D-Y
    Kim, T-Y
    Im, S-A
    BREAST, 2017, 32 : S66 - S67
  • [38] Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients
    Lim, J.
    Lee, K-H
    Min, A.
    Kim, S-G
    Kim, J-E
    Kim, T-Y
    Han, S-W
    Oh, D-Y
    Kim, T-Y
    Lim, S-A
    CANCER RESEARCH, 2017, 77
  • [39] New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation
    Corbaux, Pauline
    Sabatier, Renaud
    BULLETIN DU CANCER, 2020, 107 (10) : 959 - 960
  • [40] Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
    Dent, S.
    Cortes, J.
    Im, Y-H
    Dieras, V
    Harbeck, N.
    Krop, I. E.
    Wilson, T. R.
    Cui, N.
    Schimmoller, F.
    Hsu, J. Y.
    He, J.
    De Laurentiis, M.
    Sousa, S.
    Drullinsky, P.
    Jacot, W.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 197 - 207
12345